Pharmacotherapy of hospitalised HIV-infected patients in a general hospital during 1990, 1997 and 2001

Clinical Drug Investigation

Volumn 23, Issue 1, 2003, Pages 45-53

  De Maat, Monique M R ^a   Post, Teun M ^a   Jonker, Daniël M ^a   Mulder, Jan W ^a   Meenhorst, Pieter L ^a   Van Gorp, Eric C M ^a   Koks, Cornelis H W ^a   De Boer, Anthonius ^b   Beijnen, Jos H ^a,b  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIPROTOZOAL AGENT; ANTIRETROVIRUS AGENT; CARDIOVASCULAR AGENT; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DEXAMETHASONE; DIDANOSINE; DOMPERIDONE; FLUCONAZOLE; FOLIC ACID; FUROSEMIDE; HALOPERIDOL; HEPARIN; HORMONE; HYDROXYUREA; IMMUNOMODULATING AGENT; KETOCONAZOLE; LACTULOSE; LOPINAVIR PLUS RITONAVIR; NADROPARIN; NYSTATIN; OMEPRAZOLE; PANTOPRAZOLE; PARACETAMOL; PENTAMIDINE; POTASSIUM CHLORIDE; TEMAZEPAM; UNINDEXED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AIDS RELATED COMPLEX; ARTICLE; COMBINATION CHEMOTHERAPY; DRUG POTENTIATION; FEMALE; GENERAL HOSPITAL; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LENGTH OF STAY; MALE; NETHERLANDS; OUTPATIENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 0037253253     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200323010-00006     Document Type: Article

References (14)

1. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective study. Lancet 1999; 353: 863-8
2. Vittinghoff E, Scheer S, O'Malley P, et al. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J Infect Dis 1999; 179: 717-20
3. Berrey MM, Schacker T, Collier AC, et al. Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDS. J Infect Dis 2001; 183: 1466-75
4. Pallela FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-60
5. Torres RA, Barr M. Impact of combination therapy for HIV infection on inpatient census. N Engl J Med 1997; 336: 1531-2
6. Mouton Y, Alfandri S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalisations in 10 French AIDS reference centres. AIDS 1997; 11:F101-5
7. Beck EJ, Mandalia S, Williams I, et al. Decreased morbidity and use of hospital services in English HIV-infected individuals with increased uptake of anti-retroviral therapy 1996-1997. AIDS 1999; 13: 2157-64
8. Burger DM, Meenhorst PL, Koks CHW, et al. Zidovudine: usage and interactions: a drug utilization study in a community hospital into zidovudine, co-medication and drug interactions. Pharm Weekbl 1991; 126: 454-61
9. Anatomical Therapeutical Chemical (ATC) classification index including defined daily doses (DDDs) for plain substances. Oslo: World Health Organisation Collaborating Centre for Drug Statistics Methodology, 1994
10. Hekster YA, Vree TB, Goris RJA, et al. The defined daily dose per 100 bed-days as a unit of comparison and a parameter for studying antimicrobial drug use in a university hospital: a retrospective study of the effects of guidelines and audit on antimicrobial drug use. J Clin Hosp Pharm 1982; 7: 251-60
11. Moyle G. The role of combinations of HIV protease inhibitors in the management of persons with HIV infection. Exp Opin Invest Drugs 1998; 7: 413-26
12. Manfredi R, Calza L, Chiodo F. Ageing and HIV disease: an increasing epidemiological, clinical, and therapeutic challenge [abstract 110]. 8th European Conference on Clinical Aspects and Treatment of HIV-infection; Athens, Greece, Oct 28-32 2001
13. Mocroft A, Barry S, Sabin CA, et al. The changing pattern of admissions to a London hospital of patients with HIV: 1988-1997. AIDS 1999; 13: 1255-61
14. Lopez Bernaldo de Quiros JC, Miro JM, Peña JM, et al. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis Carinii pneumonia after highly active antiretroviral therapy in patients with HIV infecfion. N Engl J Med 2001; 344: 159-67